(HealthDay News) – Among patients with colorectal cancer (CRC), regular use of aspirin after diagnosis is associated with longer survival for those with the mutated phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene (PIK3CA), according to a study published in the Oct 25 issue of the New England Journal of Medicine.
Xiaoyun Liao, MD, PhD, from the Dana-Farber Cancer Institute in Boston, and colleagues analyzed data for 964 patients with rectal or colon cancer participating in the Nurses’ Health Study and the Health Professionals Follow-up Study, including data on aspirin use after diagnosis and PIK3CA mutation status.
Among patients with mutated-PIK3CA CRCs, the researchers found that regular use of aspirin after diagnosis correlated with significantly improved CRC-specific survival (multivariate hazard ratio [HR] for cancer-related death, 0.18) and overall survival (multivariate HR for death from any cause, 0.54). Among patients with wild-type PIK3CA cancers, there was no correlation for regular use of aspirin after diagnosis with CRC-specific survival (multivariate HR, 0.96; 95% confidence interval [CI], 0.69–1.32) or overall survival (multivariate HR, 0.94; 95% CI, 0.75–1.17).
“Regular use of aspirin after diagnosis was associated with longer survival among patients with mutated-PIK3CA CRC, but not among patients with wild-type PIK3CA cancer,” the authors write. “The findings from this molecular pathological epidemiology study suggest that the PIK3CA mutation in CRC may serve as a predictive molecular biomarker for adjuvant aspirin therapy.”
One author disclosed financial ties to several pharmaceutical companies.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)